Blog Archives for tag Boehringer-Ingelheim

Press Release – Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease

Today, Boehringer Ingelheim sent out a press release, announcing that, “…┬áthe European Commission (EC) and U.S. Food and Drug Administration… Continue reading »

Collaboration between FESCA, Scleroderma Society of Canada and Boehringer Ingelheim

In April, FESCA and the Scleroderma Society of Canada signed an agreement with Boehringer Ingelheim with the intention of working… Continue reading »

ssc_infographic_BI

What is systemic sclerosis?

We are proud to announce that with support from 2 patients – one in Italy and one in Denmark –… Continue reading »